Spire Healthcare Group (LON:SPI) Stock Price Down 22.1% on Analyst Downgrade

Spire Healthcare Group plc (LON:SPI)’s stock price dropped 22.1% on Thursday after Deutsche Bank Aktiengesellschaft lowered their price target on the stock from GBX 320 to GBX 300. Deutsche Bank Aktiengesellschaft currently has a buy rating on the stock. Spire Healthcare Group traded as low as GBX 174.60 ($2.26) and last traded at GBX 174.80 ($2.26). Approximately 1,500,525 shares were traded during mid-day trading, an increase of 157% from the average daily volume of 584,388 shares. The stock had previously closed at GBX 224.50 ($2.90).

Spire Healthcare Group Stock Performance

The stock has a 50-day moving average of GBX 227.28 and a 200 day moving average of GBX 229.74. The company has a debt-to-equity ratio of 62.25, a current ratio of 0.70 and a quick ratio of 0.74. The stock has a market capitalization of £711.58 million, a price-to-earnings ratio of 25.22, a price-to-earnings-growth ratio of 1.06 and a beta of 0.96.

Spire Healthcare Group (LON:SPI) last issued its earnings results on Thursday, March 6th. The company reported GBX 8.80 ($0.11) earnings per share (EPS) for the quarter. Spire Healthcare Group had a return on equity of 3.82% and a net margin of 1.96%. On average, analysts expect that Spire Healthcare Group plc will post 15.6634747 EPS for the current year.

About Spire Healthcare Group

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.